• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together almost 80 member organizations across the globe, united by a single purpose: driving global collaboration toward a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

Our Vision: A world free of ALS/MND

Our Aspiration: To drive global collaboration

Our Reach: We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose: Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

  • Bring focus to quality of life for PALS and their community: We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.
  • Include under-represented communities: By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.
  • Increase awareness of ALS/MND: By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.
  • Facilitate research coordination: By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.
  • Leverage collective capacity: By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.
  • Grow the community: By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Alliance Strategy 2026-2028: Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Annual Report 2024-2025: A review of the Alliance’s work and impact over the past year.

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Councils, Forums & Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Newsletter Archive
    • Newsletters
    • Meetings
  • Awards

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Ali Var, Turkey

    Ali Var, Turkey

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Olga Cosentino, Argentina

    Olga Cosentino, Argentina

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Animesh Kumar, India

    Animesh Kumar, India

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Xian-Zhang Niu, China

    Xian-Zhang Niu, China

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Cassio Fernando da Silva, Brazil

    Cassio Fernando da Silva, Brazil

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Len Johnrose, England

    Len Johnrose, England

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • David Watson, Scotland

    David Watson, Scotland

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Jay Epstein, USA

    Jay Epstein, USA

  • Liam Dwyer, England

    Liam Dwyer, England

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Christian Bär, Germany

    Christian Bär, Germany

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login